Related Experiment Video
Updated: Sep 11, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
Association between early lesion response and long-term anti-VEGF injection frequency in nAMD: a 2-year prospective
Jiaxin Pu1, Xuenan Zhuang2,3, Miaoling Li1
1Sun Yat-Sen University Zhongshan Ophthalmic Center State Key Laboratory of Ophthalmology, Guangzhou, Guangdong, China.
Purpose:
To explore the association between early response of different lesions and the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD).
Methods:
This prospective study included treatment-naïve nAMD eyes with a 2-year follow-up period. Volumetric changes of multiple lesions during the loading phase were documented, including subretinal fluid (SRF), intraretinal fluid (IRF), vascular subretinal hyper-reflective material (vSHRM) and avascular subretinal hyper-reflective material, fibrovascular pigment epithelial detachment and serous pigment epithelial detachment (sPED) and total lesion. Imaging biomarkers associated with treatment frequency were analysed for 1-year and 2-year periods.
Results:
A total of 92 eyes (92 patients) were included, with a mean age of 65.77±7.28 years. During the loading phase, all lesions except vSHRM showed significant temporal changes (p<0.05). Multivariate regression revealed that greater SRF changes at month 3 and IRF changes at month 1 were associated with increased injection frequency for both 1-year (β=0.353 and 0.360, p=0.025 and 0.022) and 2-year periods (β=0.336 and 0.293, p=0.004 and 0.026). Conversely, greater changes in vSHRM and sPED at month 2 were associated with fewer first-year injections (β=-0.307 and -0.697, p=0.023 and 0.022), while sPED changes at months 2 and 3 correlated with reduced 2-year requirements (β=-0.845 and -0.297, p=0.005 and 0.031).
Conclusion:
Enhanced absorption of SRF and IRF during early treatment was associated with increased injection frequency, while greater absorption of vSHRM and sPED correlated with reduced treatment requirements.
Trial Registration Number:
ChiCTR2200063428.

